Avoidant/Restrictive Food Intake Disorder (ARFID)
Conditions
Brief summary
Avoidant/restrictive food intake disorder (ARFID) is a serious and impairing eating disorder - occurring in up to 4% of adults - for which most individuals do not have access to treatment. The proposed study aims to develop and test a mobile app to scale delivery of cognitive-behavioral therapy for ARFID. Knowledge gained will contribute to the development of a clinically accessible, scalable, inexpensive treatment for ARFID, a highly impairing disorder for which there are significant barriers to care access.
Interventions
BEHAVIORALmCBT-AR
mCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application
Sponsors
Massachusetts General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Current avoidant/restrictive food intake disorder based on DSM-5 criteria 2. Must not have completed face-to-face CBT-AR at the Eating Disorders Clinical and Research Program at Massachusetts General Hospital 3. Ability to speak, write, and understand English 4. Residence in the United States 5. Access to an internet-connected smartphone device
Exclusion criteria
1. Underweight status (i.e., BMI \< 18.5 kg/m2) 2. Complete lack of oral intake or dependence on supplemental feeding 3. Feeding or eating disorder other than ARFID 4. Any comorbid clinically significant disorder that would require attention beyond the study treatment 6\. Medical instability requiring inpatient care according to the American Psychiatric Association 2023 treatment guidelines for eating disorders 7. Medical history of intellectual disability 8. Illiteracy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pica, ARFID, and Rumination Disorder Interview - ARFID Questionnaire (PARDI-AR-Q) | Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions) | The PARDI-AR-Q is a 32-item self-report measure based on the Pica, ARFID, and Rumination Disorder Interview that assesses ARFID diagnostic criteria and the presence and severity of each ARFID profile. Severity scores for each profile range from 0-6, with higher scores indicating greater severity. |
| Food Neophobia Scale (FNS) | Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions) | The Food Neophobia Scale is a 6-item measure that measures reluctance to try new foods. Scores range from 7-42. Higher scores on the FNS are indicative of greater behavioral responses to novel foods. |
Countries
United States
Contacts
CONTACTParaskevi Kambanis, PhD
CONTACTJonathan Xiang, BS
Outcome results
None listed